Cargando…

Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

Lower-sodium oxybate (LXB) is an oxybate medication approved to treat cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy 7 years of age and older in the United States. LXB was developed as an alternative to sodium oxybate (SXB), because the incidence of cardiovascular comorb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dauvilliers, Yves, Bogan, Richard K, Šonka, Karel, Partinen, Markku, Foldvary-Schaefer, Nancy, Thorpy, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976528/ https://www.ncbi.nlm.nih.gov/pubmed/35378745 http://dx.doi.org/10.2147/NSS.S279345

Ejemplares similares

Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2020)

Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Corrigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Narcolepsy With Cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Correction to: Changes in Cataplexy Frequency in a Clinical Trial of Lower‑Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy
por: Bogan, Richard K., et al.
Publicado: (2023)

Psychosis in Patients with Narcolepsy as an Adverse Effect of Sodium Oxybate
por: Sarkanen, Tomi, et al.
Publicado: (2014)

Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility
por: Guevarra, Jay T, et al.
Publicado: (2020)

Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials
por: Watson, Nathaniel F., et al.
Publicado: (2021)

Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice
por: Drakatos, Panagis, et al.
Publicado: (2017)

Sleep, Narcolepsy, and Sodium Oxybate
por: Mamelak, Mortimer
Publicado: (2022)

Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia
por: Thorpy, Michael J, et al.
Publicado: (2022)

Long-term follow-up on the effects of sodium oxybate on daytime sleepiness and sleep architecture in patients with narcolepsy type 1
por: Peraita-Adrados, Rosa, et al.
Publicado: (2023)

Population and Noncompartmental Pharmacokinetics of Sodium Oxybate Support Weight‐Based Dosing in Children and Adolescents With Narcolepsy With Cataplexy
por: Chen, Cuiping, et al.
Publicado: (2020)

Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials
por: Meskill, Gerard J., et al.
Publicado: (2021)

Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial
por: Dauvilliers, Yves, et al.
Publicado: (2023)

Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate
por: Schneider, Logan D, et al.
Publicado: (2023)

Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial
por: Roth, Thomas, et al.
Publicado: (2022)

The Role of Sodium Oxybate in Idiopathic Hypersomnia: A Case Report Showing Improvement of Excessive Daytime Sleepiness and Reduced Symptoms
por: Vera Ricaurte, Michael, et al.
Publicado: (2023)

Clinical and polysomnographic course of childhood narcolepsy with cataplexy
por: Pizza, Fabio, et al.
Publicado: (2013)

A randomized study of solriamfetol for excessive sleepiness in narcolepsy
por: Thorpy, Michael J., et al.
Publicado: (2019)

Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
por: Kushida, Clete A, et al.
Publicado: (2021)

Low Vitamin D in Narcolepsy with Cataplexy
por: Carlander, Bertrand, et al.
Publicado: (2011)

Off-label Sodium Oxybate in Childhood Narcolepsy: A Comprehensive Report
por: Miskoff, Jeffrey A, et al.
Publicado: (2018)

A Case of Off-label Sodium Oxybate in an 11-Year-Old with Narcolepsy
por: Miskoff, Jeffrey A, et al.
Publicado: (2019)

Reward-based behaviors and emotional processing in human with narcolepsy-cataplexy
por: Bayard, Sophie, et al.
Publicado: (2013)

Non-Dipping Blood Pressure Profile in Narcolepsy with Cataplexy
por: Dauvilliers, Yves, et al.
Publicado: (2012)

Lisdexamfetamine to improve excessive daytime sleepiness and weight management in narcolepsy: a case series
por: Aguilar, Ana C., et al.
Publicado: (2019)

Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment
por: Morse, Anne Marie, et al.
Publicado: (2023)

Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1
por: Schinkelshoek, Mink S., et al.
Publicado: (2018)

REM Sleep Behavior Disorder in Children With Type 1 Narcolepsy Treated With Sodium Oxybate
por: Antelmi, Elena, et al.
Publicado: (2021)

Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy
por: Dubow, Jordan, et al.
Publicado: (2022)

O024 Sodium oxybate for refractory narcolepsy and idiopathic hypersomnia: clinical and employment outcomes
por: Hernest, A, et al.
Publicado: (2023)

Differences in Brain Morphological Findings between Narcolepsy with and without Cataplexy
por: Nakamura, Masaki, et al.
Publicado: (2013)

Narcolepsy with cataplexy in monozygotic twins
por: Goulart, Leonardo I., et al.
Publicado: (2014)

Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing
por: Feldman, Neil T.
Publicado: (2009)

Resolution of Sleepwalking Behavior after Initiation of Sodium Oxybate in a Patient with Narcolepsy Type 2
por: Hesselbacher, Sean, et al.
Publicado: (2018)

Evaluation of Quality of Life in Patients With Narcolepsy Treated With Sodium Oxybate: Use of the 36-Item Short-Form Health Survey in a Clinical Trial
por: Bogan, Richard, et al.
Publicado: (2016)

Narcolepsy with cataplexy: Does age at diagnosis change the clinical picture?
por: Zhang, Min, et al.
Publicado: (2020)

Pharmacological Interventions for Excessive Daytime Sleepiness in Adults with Narcolepsy: A Systematic Review and Network Meta-Analysis
por: Chien, Po-Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g3v00fpcv188ge6eant9ueh9gn